Clinical Comprehensive Guide: Weill-Marchesani Syndrome (WMS)

1. Introduction and Overview

Weill-Marchesani Syndrome (WMS) is a rare, complex connective tissue disorder characterized by a constellation of distinctive physical features, primarily involving the ocular, skeletal, and cardiovascular systems. First described by Weill in 1932 and later by Marchesani in 1939, this syndrome is clinically defined by short stature, brachydactyly (short, stubby fingers and toes), joint stiffness, and specific ocular abnormalities, most notably microspherophakia (small, spherical lenses).

The syndrome is genetically heterogeneous, exhibiting both autosomal recessive and autosomal dominant patterns of inheritance. Because of its multi-systemic impact, patients often require a multidisciplinary approach involving ophthalmologists, orthopedists, cardiologists, and geneticists. While the prevalence is estimated at approximately 1 in 100,000, it is likely underdiagnosed due to phenotypic variability.

2. Technical Specifications and Pathophysiology

Etiology and Molecular Mechanisms

WMS is caused by mutations in genes involved in the extracellular matrix (ECM) and the regulation of transforming growth factor-beta (TGF-β) signaling. The two primary genes identified are:

• ADAMTS10 (Autosomal Recessive): Mutations here disrupt the ADAMTS10 protein, a secreted metalloprotease essential for fibrillin microfibril assembly. This leads to impaired ECM integrity.
• FBN1 (Autosomal Dominant): While FBN1 mutations are classically associated with Marfan Syndrome, specific mutations within this gene can manifest as the WMS phenotype, suggesting an overlapping spectrum of fibrillinopathy.
• LTBP2 (Autosomal Recessive): Mutations in the Latent TGF-β Binding Protein 2 also contribute to the recessive form of WMS, primarily affecting ocular development.

Pathophysiological Cascade

The fundamental mechanism involves the dysregulation of the TGF-β signaling pathway. Fibrillin-1 and ADAMTS10 are critical for sequestering TGF-β in the ECM. When these proteins are dysfunctional, TGF-β bioavailability is altered, leading to:
1. Impaired Skeletal Maturation: Premature fusion of growth plates (epiphyses), resulting in short stature.
2. Ligamentous/Tendon Abnormalities: Excessive collagen deposition or structural weakness in connective tissues, leading to joint rigidity.
3. Ocular Morphology: Disruption of the zonular fibers (which hold the lens in place), causing microspherophakia and lens dislocation.

3. Clinical Indications and Physical Presentation

The diagnosis of WMS is clinical, based on the presence of the "Weill-Marchesani triad": ocular, skeletal, and cardiovascular manifestations.

Ocular Findings

Ocular symptoms are the most serious and often the primary reason for clinical consultation.
* Microspherophakia: The lens is abnormally small and spherical rather than biconvex.
* Ectopia Lentis: The lens is frequently displaced (subluxated), most commonly downward (inferiorly).
* Secondary Glaucoma: The spherical lens can block the pupil (pupillary block), preventing aqueous humor outflow, leading to acute or chronic angle-closure glaucoma.

Skeletal and Orthopedic Findings

• Brachydactyly: Shortening of the metacarpals and phalanges.
• Short Stature: Adult height is typically well below the 5th percentile.
• Joint Stiffness: Reduced range of motion in the fingers, wrists, and elbows.
• Hyper-muscularity: Patients often present with a "stocky" or "athletic" build, sometimes described as having a hypertrophic appearance.

Clinical Staging/Grading Table

4. Differential Diagnosis

WMS must be distinguished from other connective tissue disorders. Clinicians should use the following table to rule out mimics:

5. Diagnostic Testing Protocols

A definitive diagnosis relies on a combination of clinical assessment and genetic confirmation.

1. Ophthalmological Examination:
   • Slit-lamp biomicroscopy: Essential for identifying microspherophakia and assessing the zonular fibers.
   • Tonometry: Mandatory for monitoring intraocular pressure (IOP) to detect glaucoma.
   • Cycloplegic Refraction: To assess the refractive status caused by the abnormal lens shape.
2. Radiographic Imaging:
   • Hand/Wrist X-rays: To document brachydactyly and advanced bone age or early epiphyseal closure.
   • Echocardiogram: To evaluate for valvular heart disease (mitral valve prolapse or aortic root dilation).
3. Genetic Testing:
   • Targeted gene sequencing (ADAMTS10, FBN1, LTBP2) is the gold standard for confirming the inheritance pattern and providing genetic counseling for families.

6. Risks, Side Effects, and Complications

Ocular Risks

The most immediate threat to health is acute angle-closure glaucoma. The spherical lens moves forward, pushing the iris against the cornea, obstructing the trabecular meshwork. This requires immediate intervention (laser peripheral iridotomy or surgical lens extraction).

Cardiovascular Risks

While less common than in Marfan syndrome, patients may develop aortic root dilation or mitral valve dysfunction. Regular cardiac monitoring is required.

Orthopedic Risks

Joint contractures can lead to functional impairment in daily living activities. Early physical therapy is recommended to maintain range of motion.

7. Management and Prognosis

There is no cure for WMS; management is purely symptomatic.
* Ophthalmology: Prophylactic laser iridotomy is often performed to prevent acute glaucoma. If the lens dislocates or glaucoma becomes unmanageable, lens extraction (lensectomy) is necessary.
* Orthopedics: Physical therapy and occupational therapy to manage joint stiffness.
* Prognosis: Life expectancy is generally normal. The primary morbidity is vision loss, which is preventable with early and aggressive ophthalmological monitoring.

8. Frequently Asked Questions (FAQ)

1. Is Weill-Marchesani Syndrome fatal?

No, WMS is not typically fatal. Life expectancy is generally within normal ranges, provided that cardiac and ocular complications are managed.

2. What is the most dangerous symptom of WMS?

The most dangerous symptom is acute angle-closure glaucoma, which can lead to permanent vision loss if not treated immediately.

3. Does WMS affect intelligence?

No. Unlike some other genetic syndromes, WMS is not associated with intellectual disability or cognitive impairment.

4. Can physical therapy help with joint stiffness?

Yes, consistent physical therapy can help maintain range of motion in the joints, particularly in the hands and wrists, improving quality of life.

5. How often should a patient with WMS see an ophthalmologist?

Patients should undergo comprehensive eye exams at least every 6 months, or more frequently if intraocular pressure is elevated.

6. Is genetic testing available for family members?

Yes. Once a mutation is identified in the proband, cascade testing for at-risk family members is highly recommended for family planning.

7. Why do patients with WMS look "muscular"?

The syndrome is characterized by a specific body habitus that includes a high muscle-to-fat ratio, often giving a stocky or hyper-muscular appearance despite the short stature.

8. Is surgery required for the lens?

Surgery (lensectomy) is indicated when the lens causes pupillary block, uncontrollable glaucoma, or significant vision impairment due to subluxation.

9. Are there cardiovascular issues to worry about?

Yes, some patients experience mitral valve prolapse or valvular stenosis. An annual echocardiogram is recommended for baseline monitoring.

10. Can WMS be diagnosed during pregnancy?

If the family history is known and the specific mutation is identified, prenatal diagnosis via amniocentesis or chorionic villus sampling is possible.

9. Conclusion

Weill-Marchesani Syndrome is a rare but clinically significant condition that demands a high index of suspicion from clinicians. By focusing on the early detection of ocular abnormalities and maintaining a rigorous surveillance schedule for skeletal and cardiac health, medical professionals can significantly improve the long-term outcomes for these patients. As our understanding of the TGF-β signaling pathway evolves, future therapies may move beyond symptom management toward targeted molecular interventions.

Disclaimer: This guide is intended for educational purposes for healthcare professionals and students. It does not replace professional clinical judgment. Always consult current clinical guidelines and genetic counseling resources for individual patient care.